Scholars Central

Conference abstract

Streptococcus pyogenes candidate vaccine

Authors: Luiza Guilherme

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Group A Streptococci (GAS) diseases remain as a public health problem both in industrialized and development countries, leading to severe invasive infections, pharyngitis and pyoderma. These diseases can lead to autoimmune post-streptococcal sequelaein non-treated patients as Rheumatic Fever (RF) that affects children and young people and is caused by molecular mimicry with human proteins in which auto reactive B and T cells play an important role. Rheumatic Heart Disease (RHD) is the most severe sequel characterized by progressive and permanent valvular lesions. At least 517 000 people die per year due to severe GAS diseases. The prevalence of RHD is 15.6 million cases with 2, 82, 000 new cases 2, 33, 000 deaths each year. In Brazil, according to the WHO epidemiological model and data from IBGE (Brazilian Institute of Geography and Statistics), there are approximately 10 million cases of Streptococcal pharyngitis infections. These cases could lead to 30,000 new cases of RF, among which approximately 15,000 could become cardiac lesions. One important aspect of the recurrence of rheumatic fever episodes is the possibility of worsening valve damage. The vaccine we are developing against S. pyogenesis based on protective epitopes of C-terminal portion of the M protein. A peptide with 55 amino acids named StreptInCor (medical identity) was designed. The advantage of the StreptIncor vaccine model is the possibility of the vaccine epitope undergoing processing by antigen presenting cells (monocytes and/or macrophages) to generate several peptides that induce both B and T immune responses, resulting in a safe and robust immune response. Experimental assays have demonstrated that the StreptInCor peptide induces high titers of opsonic and neutralizing and protective antibodies in outbred immunized mice. Using HLA class II transgenic mice, it was possible to evaluate the immunogenicity and safety of the StreptInCor vaccine epitope for a period of one year. Specific and non-autoreactive antibodies were produced. No autoimmune or pathological reactions were observed in the heart or other organs. StreptInCor vaccine also induces regulatory T cells (Treg) that strongly indicate that the vaccine peptide may have therapeutic potential to control both inflammatory and autoimmune response in RF/RHD patients.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Journal of Vaccines & Vaccination.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Vaccines & Vaccination
  • SubjectVaccines & Immunisation
  • BylineArticles whose byline prints “Luiza Guilherme”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels